Protea Biosciences


Press release   •   May 16, 2012 04:56 EDT

16th May 2012-Protea Biosciences expands into a new facility and provides new high resolution MS-based imaging capabilities using proprietary LAESI technology.

Protea Biosciences, a leading developer of technologies and services for biomolecular analysis, announced that the company is expanding its bioanalytical services business into a new, state-of-the-art 11,000 sq. ft. facility, providing innovative mass spectrometry services to the biopharma market. 

The facility is located in Morgantown, WV. The new space will advance the continued growth of the current mass spectrometry services business by providing additional instrumentation and increased analytical capabilities, including the use of the LAESI DP-1000 system for distribution profiling of biomolecules.

This expansion allows Protea Bio to better support its customers by increasing overall service
capabilities, and it enables the enhancement of a portfolio of solutions. 

The addition of LAESI-based services gives Protea the opportunity to perform direct ionization and 2D-3D mapping of biological samples, without the need for time consuming sample preparation, which will increase our overall throughput and empower researchers with data that was previously unimaginable.

The Bioanalytical Services Division specializes in services including, biomarker discovery, absolute quantitation of large molecules, MRM-based assays, and global proteome characterization. The LAESI-based services on the proprietary LAESI DP-1000 system will include analysis of tissues, living cells and colonies, TLC plate mapping, as well as high throughput biofluid analysis and molecular quantitation studies.

Protea's Bioanalytical Services Division has always been focused on providing domain expertise and innovation to support projects from concept to knowledge using its large portfolio of low and high resolution mass spectrometry technologies. This expansion supports the increased demand for advanced bioanalytical studies in order to better serve research organizations and biopharma companies during drug discovery and development cycle.

Protea is a leader in the field of bioanalytics - the identification and characterization of proteins,
metabolites, and other biomolecules, which are the products of all living cells and life forms -
technology that is foundational for all pharmaceutical and life science research.

Protea Biosciences, is a company that uses new technology to learn more about cancer and other diseases.